This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


AVEO Pharmaceuticals, Inc.

Drug Names(s): SCH900105, AV-299

Description: SCH900105 (AV-299) is a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). HGF is the soluble ligand for the c-Met receptor tyrosine kinase. Preclinical studies have provided strong evidence that signaling through the HGF/c-Met pathway mediates several cellular functions involved in tumor growth and metastasis, such as cell proliferation, angiogenesis, survival, migration, and invasion. Numerous studies have demonstrated a correlation between high HGF levels and poor prognosis in a wide variety of human malignancies including gastric, breast, and lung, suggesting that targeting HGF may provide a novel way of treating a broad range of cancers.

To guide the clinical development of SCH900105 (AV-299), AVEO is using its proprietary, genetically engineered models of human cancer to identify specific characteristics of tumors in which the HGF/c-Met pathway plays a critical role in tumor maintenance, as opposed to those in which the pathway is activated but not essential.

Deal Structure: AVEO and XOMA
In April 2006, XOMA entered into an agreement with AVEO to utilize XOMA's Human Engineering technology to humanize AV-299. XOMA created four Human Engineered versions of the original AV-299, all of which met design goals and were delivered ahead of schedule. From these four versions, AVEO selected one as its lead development candidate. For work conducted and licenses granted, XOMA received an up-front license fee and is eligible for development milestones and royalty payments on sales of AV-299. AVEO retains all development and commercialization rights to AV-299.

AVEO and Schering-Plough (now Merck)
In April 2007, AVEO announced that it had entered an exclusive worldwide license and development agreement with Schering-Plough for SCH900105 (AV-299). AVEO will have primary responsibility for clinical development of SCH900105 (AV-299) through proof-of-concept in man and will apply its HRPTM platform during a multi-year translational research...See full deal structure in Biomedtracker

Partners: XOMA Corporation

Ficlatuzumab News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug